Trump administration's guidance on emergency care law adds to ‘chaos,' not clarity, in states with strict abortion laws, some doctors say
Abortion rights
Maternal health
Women's healthFacebookTweetLink
Follow
Federal guidance that the Trump administration says is intended to offer clarity is instead leaving health care providers even more confused about whether they can provide an abortion in an emergency, particularly in states with strict abortion laws.
This month, the Trump administration rescinded 2022 federal guidance specifying that under the Emergency Medical Treatment and Labor Act, or EMTALA, people should be able to get an abortion if a medical emergency makes it necessary, even in states with laws that restrict such procedures. HHS and the Centers for Medicare & Medicaid Services said they would continue to enforce the federal law, specifying that the policy included emergency medical conditions that placed the health of a pregnant woman or her unborn child in serious jeopardy.
Then, in a letter to health care providers last week, US Health and Human Services Secretary Robert F. Kennedy Jr. emphasized that under EMTALA, stabilizing care should be given to a person who is pregnant and having a medical emergency – but it doesn't specify what that care might involve.
In the June 13 letter, Kennedy says that it was the 2022 memo that 'created confusion. But that is no more.'
Some doctors beg to differ.
It's unclear exactly what the recision of the previous guidance meant for emergency care, particularly in states with highly restrictive abortion laws, some doctors said. The latest letter doesn't mention abortion at all — and the absence of specifics is creating more uncertainty.
'I do think this just contributes to all of the chaos that clinicians are having to deal with as they just attempt to take care of the patient in front of them and navigate state laws and federal guidance to provide care for patients,' said Dr. Nisha Verma, a practicing obstetrician-gynecologist and senior adviser for reproductive health policy and advocacy at the American College of Obstetricians and Gynecologists, a professional organization that represents the majority of practitioners in the United States. 'It's not something you want to get wrong, because the consequences are so severe and it feels so scary.'
Verma appreciates that the new letter from Kennedy clarifies that EMTALA is still the law of the land, even after the administration rescinded the 2022 guidance. But without a specific mention of abortion, she said, the nation's patchwork of laws makes it difficult for doctors to navigate emergency situations. Some of those state laws could even send doctors to jail if they make the wrong decision about when an emergency necessitates an abortion.
'I think it was helpful to specify abortion is covered under EMTALA' in the 2022 guidance, Verma said. 'I do think that having that language specifically in this really scary, chilling environment was helpful.'
Dr. Alison Haddock, an emergency room doctor who is president of American College of Emergency Physicians, said she was happy that Kennedy's letter confirmed that pregnant patients need access to care and that it included examples of common problems like miscarriages, ectopic pregnancies and premature rupture of membranes.
'Those are some of the situations that have been really challenging for our physicians. Noting that those can represent an obstetric emergency where EMTALA would apply is really good to see,' Haddock said.
But she added that the Trump administration's guidance does not clear up everything.
'I think physicians are still going to have issues with conflicting state law where they are still going to be left in a gray area of uncertainty about how to balance adhering to EMTALA and adhering to state law, and that's going to leave patients in the same place,' Haddock said.
Trips to the emergency room are common for pregnant people, studies show. The majority of emergency providers say they treat pregnant patients in virtually every shift, according to the American College of Obstetricians and Gynecologists, and in some circumstances, treatment to protect a pregnant person's health or life may require an abortion.
Pregnancy emergencies don't always happen during standard work hours, Haddock said, and the 'ability to convene the ethics committee at 2 a.m. is very limited, and then it can be a lot of layers to get through at the hospital.'
Haddock said her association sent a letter to its members encouraging them to advocate for clearer guidance from their own hospitals.
'Achieving greater clarity on this is really important to make sure physicians feel like they have the protections they need to provide lifesaving medical care,' she added.
Specifics have been important when it comes to EMTALA. When it became federal law in 1986, some hospitals refused to care for uninsured women in labor, so in 1989, Congress spelled out that pregnant people who were having contractions had to be given emergency care even if they couldn't pay for it.
In 2021, guidance from the Biden administration added more specifics, saying it was a doctor's duty to provide stabilizing treatment that 'preempts any directly conflicting state law or mandate that might otherwise prohibit or prevent such treatment.'
However, it wasn't until the 2022 guidance that it was spelled out that an abortion had to be provided when necessary.
The Biden administration guidance was meant to eliminate confusion in states with anti-abortion laws that did not include an exception for the life or health of a pregnant person, and it stated that federal law preempted the state statutes in the case of such laws.
That memo was issued just weeks after the US Supreme Court overturned Roe v. Wade, the 1973 ruling that gave pregnant people a constitutional right to an abortion.
A case before the court last year would have clarified whether federal law requires health care services to provide access to emergency care in every state, regardless of abortion laws, but the high court sent it back to the lower courts. In March, the Trump administration dropped the lawsuit. Some legal experts interpreted that as a signal that the administration would not enforce EMTALA.
Even when the 2022 guidance was in place, provider surveys in states that criminalized abortion found that doctors were operating in 'chaos and confusion,' said Payal Shah, director of research, legal and advocacy with the Physicians for Human Rights a Nobel Peace Prize-winning medical and human rights organization. Providers were still having a hard time determining whether EMTALA really would protect them if they had to perform an abortion, even in an emergency situation.
'Criminalization causes fear, and then clinicians feel paralyzed,' Shah said. 'They don't feel like they have the authority to make decisions about reproductive health care in line with their medical judgment and medical ethics and pregnant patients' preferences. Instead, it becomes a legal decision.'
After the Dobbs decision removed the federal right to an abortion in 2022, some women died after doctors told them it would be a 'crime' to intervene in a miscarriage or they couldn't access timely medical care. Idaho's strict abortion law has led some doctors to tell pregnant patients that they should consider buying 'life flight insurance' in case a local hospital wouldn't be able to take care of a pregnancy complication.
Rescinding the 2022 guidance will probably make stories like these more common, several experts said.
'Rescinding this guidance serves no purpose other than to try to strengthen or deepen that confusion,' Shah said. 'This is an attempt to gaslight the American public and to say that criminalization of abortion is working. Criminalization is not working, and that is something the evidence really shows.'
Alexa Kolbi-Molinas, deputy director of the ACLU's Reproductive Freedom Project, interprets the new HHS letter to mean the law does require emergency abortion care, but she added that the administration's actions on the matter 'have been reckless at best and outright dangerous at worst.'
'The Trump administration is scrambling to clean up a mess entirely of its own making,' Kolbi-Molinas said in an email. 'The law has been clear for forty years: pregnant patients who go to a hospital in medical crisis must receive health- and lifesaving care, regardless of state law. If the administration had not rescinded the previous guidance reaffirming hospitals' obligations to provide this care earlier this month, there would have been no need to issue Friday's letter.'
HHS did not respond to direct questions about what 'stabilizing care' meant and whether its interpretation of EMTALA included abortion as stabilizing care. Instead, a spokesperson for the agency sent a link to a June 4 message on X from Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services.
'Don't believe the spin and fearmongering of the fake news,' the post said. 'The Biden Administration created confusion, but EMTALA is clear and the law has not changed: women will receive care for miscarriage, ectopic pregnancy, and medical emergencies in all fifty states- this has not and will never change in the Trump Administration.'
'To me, this question remains: Why won't they use the word 'abortion' if they really believe that abortion is sometimes part of emergency medical care for pregnant people? They won't do it,' said Rebecca Hart Holder, president of Reproductive Equity Now.
'If the Trump administration or Secretary Kennedy truly intended to reassure providers that abortion in the case of a medical emergency, is protected under EMTALA, they would have used those words explicitly as a qualifying example of emergency medical care,' Hart Holder added. 'I think it's a fair assumption to make that even more people are going to die when they're in emergency situations.'
In the wake of Dobbs, the Kennedy letter presents another potential problem, said reproductive law expert Rolonda Donelson.
'In the letter, he mentions that EMTALA requires caring for the pregnant woman and their unborn child. Pre-Dobbs, that might not have meant much, but post-Dobbs, with the rise in fetal personhood in state abortion bans, it raises questions on whether the providers in these emergency departments have any duty to the unborn fetus and whether they can provide this emergency stabilizing care when it conflicts with their state abortion ban,' said Donelson, the Huber Reproductive Health Equity Legal Fellow at the National Partnership for Women & Families.
'This guidance does not provide any clarification. It increases chaos and confusion among patients, providers and everyone on whether they can go into an emergency department if they're experiencing a medical emergency and receive an abortion as necessary stabilizing care.'
In March, concerned that even more clarity was needed, 88 lawmakers reintroduced a resolution that affirmed EMTALA protects access to emergency abortion care. But even if such a bill were to make its way through Congress, it's unclear whether Trump would sign it.
In the absence of additional legislation, legal experts say, the confusion will continue placing an unfair burden on doctors and patients.
'It's unrealistic to have doctors who should be saving patient lives and doing all of those important things to try and also be lawyers and policy advocates and figure out the nitty gritty of what these things mean,' Donelson said.
But it's important for patients to know, she said, that they should go to an emergency room if they are experiencing a medical emergency.
'The last thing I would want is a pregant person who is experiencing a medical emergency to think that they won't be able to get care at a hospital and forgo going and then something bad happen to them.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
24 minutes ago
- Medscape
ASCO 2025: New Standards Reshape Care in mBC
Heather McArthur, MD, describes how the 2025 ASCO Annual Meeting brought exciting advances in the metastatic breast cancer space. In PD-L1-positive triple-negative breast cancer, sacituzumab govitecan combined with pembrolizumab significantly improved progression-free survival over standard chemotherapy plus pembrolizumab, quickly becoming a new standard of care. Similarly, in HER2-positive disease, trastuzumab deruxtecan combined with pertuzumab outperformed traditional THP therapy, offering a new frontline option. Overall, these findings signify a major shift in how to treat metastatic breast cancer.
Health Line
24 minutes ago
- Health Line
Stages of Crohn's Disease
Key takeaways Crohn's disease symptoms can be mild, moderate, or severe. It's a progressive disease, but its stages are hard to determine because each person's condition progresses differently. The earlier you treat and manage Crohn's, the more likely you are to reduce your chance of developing more severe symptoms. There's no cure for Crohn's disease, but medications and lifestyle changes can help manage the condition. This is why it's crucial to identify the disease when symptoms are still mild. Crohn's disease is a type of inflammatory bowel disease (IBD). It's considered a chronic condition, which means that you'll have it for your entire life. The exact cause of Crohn's is unknown. It most often develops in your late teens or 20s. Crohn's disease is marked by inflammation of the gastrointestinal (GI) tract. The inflammation can appear anywhere in the GI tract, from the mouth to the anus. What are the stages of Crohn's disease? Crohn's is a progressive disease that starts with mild symptoms and gradually gets worse. With mild to moderate Crohn's, you may experience diarrhea or abdominal pain, but you won't experience other symptoms or complications. You're able to move, eat, and drink as normal, and the disease has a minimal impact on your quality of life. In some cases, you won't even require treatment. If you have moderate to severe Crohn's disease, you may experience diarrhea or abdominal pain, as well as additional symptoms and complications, such as fever or anemia. If your Crohn's is severe, you might be in constant pain and discomfort, and you may need to use the bathroom frequently. That said, it's difficult to classify Crohn's disease into stages because people tend to experience ups and downs in symptoms. What progression looks like can be different for each person, and treatment can affect your outlook. How quickly does Crohn's disease progress? Over time, Crohn's can cause damage to the intestines and lead to potential complications such as strictures, fistulas, and abscesses. Stricture means that a portion of the intestine becomes narrower due to scar tissue on its wall. While there's no time frame for how long it would take for such complications to develop, there are risk factors that may speed up progression. These include: being under 30 years old having a history of smoking having ulcers found in a colonoscopy having the long bowel segments affected by the disease having anal inflammation having symptoms that go beyond the intestinal system, such as in the eyes, skin, liver, or joints having a history of bowel resections At diagnosis, 10% of people already have strictures, and an additional 15% to 20% will develop them within the next 10 to 20 years. Five types of Crohn's disease Progression may also depend on the type of Crohn's disease you have. These are: ileocolitis ileitis gastroduodenal Crohn's disease diffuse jejunoileitis Crohn's colitis Crohn's disease progression patterns The patterns by which Crohn's might progress are: Chronic relapsing: With this progression type, you typically experience at least 12 months of remission before experiencing a flare. Common symptoms of a Crohn's disease flare-up may include diarrhea, abdominal pain, weight loss, blood in stool, and fatigue. Remission: Remission means that your symptoms improve or disappear completely. Various studies show most people will relapse within 8 years of diagnosis, with a 43% to 45% remission rate after 10 years. But if you stay in remission for a year, there's an 80% chance remission will continue for the next year. Improved and stable: This is when your condition has progressed to having no symptoms and has remained this way, though signs of the disease might still show up on tests. Chronic refractory: This means you continue to show symptoms without any breaks or remission. About 10% to 15% of people with Crohn's experience a chronic refractory disease course. That said, even different people living with the same Crohn's pattern might progress differently. Genetics, type of treatment, and surgery are also factors that may affect which disease course you follow. The earlier you treat and manage Crohn's, the more likely you are to reduce your chance of developing more severe symptoms. What is the life expectancy of someone with Crohn's disease? There's no cure for Crohn's disease, though many people can live fulfilling lives with long periods of remission. That said, although there's been an increase in life expectancy for people living with inflammatory bowel diseases (IBDs), the life expectancy of Crohn's is still lower compared to those without IBDs for both males and females. When Crohn's causes complications, it can, in rare cases, lead to death. Common causes of death include cancer, heart disease, and infection. What are the early symptoms of Crohn's disease? In Crohn's disease, healthy cells in the GI tract attack themselves, causing inflammation. As a result, you'll likely experience a range of symptoms. Early signs of Crohn's disease include: frequent cramps ongoing abdominal pain frequent diarrhea bloody stools unintentional weight loss As the disease progresses, you may start feeling fatigued and even develop anemia. You may also experience nausea from constant irritation of the GI tract. In addition, you may start experiencing symptoms outside of the GI tract. These symptoms include: eye pain fever joint inflammation and pain red skin rashes and bumps mouth sores Early diagnosis is important to help prevent damage to the intestines. If you experience these symptoms and have a family history of Crohn's, you should ask your doctor for testing. How is Crohn's disease treated and managed? Medications can treat inflammation and stop your body from attacking its own cells. As your symptoms progress, your gastroenterologist may also recommend occasional bowel rest. However, not all doctors agree with this measure. A bowel rest involves a strict diet of only liquids for a few days. The purpose is to let the GI tract heal from inflammation and essentially take a break. To prevent malnutrition, you may need an IV. Talk with your doctor before switching to a liquid diet. Following this, your doctor may follow a special Crohn's diet and take supplements. You also may need to take pain medication. Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin), as these can make Crohn's worse. Instead, ask your doctor if you can safely take acetaminophen (Tylenol). You may need surgery if your symptoms become life threatening. Around 67% to 75% of all people with Crohn's will eventually need surgery, according to the Crohn's & Colitis Foundation. Surgery can't cure the disease, but it may help repair severely damaged tissues and remove blockages.
Health Line
24 minutes ago
- Health Line
Current and Breakthrough Treatments for Chronic Lymphocytic Leukemia (CLL)
Key takeaways Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the immune system. Because it's slow growing, many people with CLL won't need to start treatment for many years after their diagnosis. Once the cancer begins to grow, many treatment options are available that can help people go into remission. This means people can experience long periods of time when there's no sign of cancer in their bodies. While there's no cure for CLL yet, breakthroughs in the field are on the horizon. A large number of approaches are under investigation to treat CLL, including drug combinations and CAR T-cell therapy. Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the immune system. Because it's slow-growing, many people with CLL won't need to start treatment for many years after their diagnosis. Once the cancer begins to grow, there are many available treatment options that can help people achieve remission. This means people can experience long periods of time when there's no sign of cancer in their bodies. The exact treatment option that you'll receive depends on a variety of factors. This includes: whether your CLL is symptomatic the stage of the CLL, based on results of blood tests and a physical exam your age your overall health While there's no cure for CLL yet, breakthroughs in the field are on the horizon. Treatments for low risk CLL Doctors typically stage CLL using a system called the Rai system. Low risk CLL describes people who fall in 'stage 0' under the Rai system. In stage 0, the lymph nodes, spleen, and liver are not enlarged. Red blood cell and platelet counts are also near normal. If you have low risk CLL, your doctor (usually a hematologist or oncologist) will likely advise you to ' watch and wait ' for symptoms. This approach is also called active surveillance. Someone with low risk CLL may not need further treatment for many years. Some people will never need treatment. You'll still need to see a doctor for regular checkups and lab tests. Treatments for intermediate or high risk CLL Intermediate risk CLL describes people with stage 1 to stage 2 CLL, according to the Rai system. People with stage 1 or 2 CLL have enlarged lymph nodes and potentially an enlarged spleen and liver but close to normal red blood cell and platelet counts. High risk CLL describes patients with stage 3 or stage 4 cancer. This means you may have an enlarged spleen, liver, or lymph nodes. Low red blood cell counts are also common. In the highest stage, platelet counts may be low as well. If you have intermediate or high risk CLL, your doctor will likely recommend that you start treatment right away. Chemotherapy and immunotherapy In the past, the standard treatment for CLL included a combination of chemotherapy and immunotherapy agents, such as: a combination of fludarabine and cyclophosphamide (FC) FC plus an antibody immunotherapy known as rituximab (Rituxan) for people younger than 65 bendamustine (Treanda) plus rituximab for people older than 65 chemotherapy in combination with other immunotherapies, such as alemtuzumab (Campath), obinutuzumab (Gazyva), and ofatumumab (Arzerra). These options may be used if the first round of treatment doesn't work. Targeted therapies Over the last few years, a better understanding of the biology of CLL has led to a number of more targeted therapies. These drugs are called targeted therapies because they're directed at specific proteins that help CLL cells grow. Examples of targeted drugs for CLL include: zanubrutinib (Brukinsa): Approved by the Food and Drug Administration (FDA) in 2023, zanubrutinib targets the enzyme known as Bruton's tyrosine kinase (BTK), which is crucial for CLL cell survival. ibrutinib (Imbruvica): This targets BTK with less precision than zanubrutinib. venetoclax (Venclexta): This used in combination with obinutuzumab (Gazyva), targets the BCL2 protein, a protein seen in CLL. idelalisib (Zydelig): This blocks the kinase protein known as PI3K and is used for relapsed CLL. duvelisib (Copiktra): This also targets PI3K but is typically used only after other treatments fail. acalabrutinib (Calquence): This is another BTK inhibitor approved in late 2019 for treating CLL. Monoclonal antibody therapies Monoclonal antibody therapies are a type of treatment in which proteins are made in a laboratory and designed to target certain antigens. They help jolt your immune system into attacking the cancer cells. There are several monoclonal antibody treatments approved for treating CLL by targeting the antigens CD20 and CD52: rituximab (Rituxan): targets CD20, often used with chemotherapy or targeted therapy as part of the initial treatment or in the second-line treatment obinutuzumab (Gazyva): targets CD20, used with venetoclax (Venclexta) or chlorambucil (Leukeran) for patients with previously untreated CLL ofatumumab (Arzerra): targets CD20, usually used in patients whose disease has not responded to prior treatments and is given in combination with chlorambucil (Leukeran) or FC alemtuzumab (Campath): targets CD52 Blood transfusions You may need to receive intravenous (IV) blood transfusions to increase blood cell counts. Radiation Radiation therapy uses high-energy particles or waves to help kill cancer cells and shrink painful, enlarged lymph nodes. Radiation therapy is rarely used in CLL treatment. Stem cell and bone marrow transplants Your doctor may recommend a stem cell transplant if your cancer doesn't respond to other treatments. A stem cell transplant allows you to receive higher doses of chemotherapy to kill more cancer cells. Higher doses of chemotherapy can cause damage to your bone marrow. To replace these cells, you'll need to receive additional stem cells or bone marrow from a healthy donor. Breakthrough treatments A large number of approaches are under investigation to treat people with CLL. Some have been recently approved by the FDA. Drug combinations In May 2019, the FDA approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) to treat people with previously untreated CLL as a chemotherapy-free option. In April 2020, the FDA approved a combination therapy of rituximab (Rituxan) and ibrutinib (Imbruvica) for adult patients with chronic CLL. These combinations make it more likely that people may be able to do without chemotherapy altogether in the future. Nonchemotherapy treatment regimens are essential for those who can't tolerate harsh chemotherapy-related side effects. CAR T-cell therapy One of the most promising future treatment options for CLL is CAR T-cell therapy. CAR T-cell therapy, which stands for chimeric antigen receptor T-cell therapy, uses a person's own immune system cells to fight cancer. The procedure involves extracting and altering a person's immune cells to better recognize and destroy cancer cells. The cells are then put back into the body to multiply and fight off the cancer. CAR T-cell therapy research is still ongoing. In September 2023, researchers reported a possible 'universal' CAR T-cell treatment that may be effective in all types of blood cancers. CAR T-cell therapies are promising, but they do carry risks. One risk is a condition called cytokine release syndrome. This is an inflammatory response caused by the infused CAR T-cells. Some people can experience severe reactions that may lead to death if not quickly treated. Other drugs under investigation Some other targeted drugs currently being evaluated in clinical trials for CLL include: entospletinib (GS-9973) tirabrutinib (ONO-4059 or GS-4059) cirmtuzumab (UC-961) ublituximab (TG-1101) pembrolizumab (Keytruda) nivolumab (Opdivo) Once clinical trials are completed, some of these drugs may be approved for treating CLL. Talk with a doctor about joining a clinical trial, especially if current treatment options aren't working for you. Clinical trials evaluate the efficacy of new drugs as well as combinations of already approved drugs. These new treatments may work better for you than the ones currently available. Hundreds of clinical trials are ongoing for CLL.
